-
公开(公告)号：US10730924B2
公开(公告)日：2020-08-04
申请号：US16025302
申请日：2018-07-02
Applicant: ModernaTX, Inc.
Inventor： Barry Ticho , Nadege Briancon-Eris , Zhinan Xia , Athanasios Dousis , Seymour de Picciotto , Vladimir Presnyak , Stephen Hoge , Iain Mcfadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: C12N15/62 , A61K47/14 , C07K14/64 , A61K31/7105 , A61K47/69 , A61P9/00 , A61K38/17 , C07K16/26 , C12N15/52 , A61K9/127 , A61K38/00 , A61K9/00
Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
-
公开(公告)号：US20200030432A1
公开(公告)日：2020-01-30
申请号：US16494988
申请日：2018-03-16
Applicant: ModernaTX, Inc.
Inventor： Giuseppe Ciaramella , Sunny Himansu , Vladimir Presnyak , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K39/12 , A61K31/7115 , A61P31/14 , C12N15/86
Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
-
公开(公告)号：US10406113B2
公开(公告)日：2019-09-10
申请号：US16222155
申请日：2018-12-17
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Ailin Bai , Vladimir Presnyak , Stephen Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K48/00 , A61K9/51 , A61K38/17 , A61K38/20 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US10172808B2
公开(公告)日：2019-01-08
申请号：US15995889
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Ailin Bai , Vladimir Presnyak , Stephen Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K48/00 , A61K31/7115 , A61K9/51 , A61K38/20 , A61K38/17 , C07K14/54 , C07K14/705 , A61K39/395 , A61K9/00 , A61P35/00 , A61K39/00
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20180371047A1
公开(公告)日：2018-12-27
申请号：US16025302
申请日：2018-07-02
Applicant: ModernaTX, Inc.
Inventor： Barry Ticho , Nadege Briancon-Eris , Zhinan Xia , Athanasios Dousis , Seymour de Picciotto , Vladimir Presnyak , Stephen Hoge , Iain Mcfadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
-
Patent Agency Ranking
公开(公告)号：US20170210697A1
公开(公告)日：2017-07-27
申请号：US15476253
申请日：2017-03-31
Applicant: MODERNATX, Inc.
IPC: C07C229/12 , C07K14/505 , A61K38/18 , A61K9/16 , A61K48/00
CPC classification number: C07C229/12 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K9/1617 , A61K9/1641 , A61K9/5123 , A61K9/5146 , A61K31/7105 , A61K38/1725 , A61K38/1816 , A61K47/543 , A61K47/6911 , A61K48/00 , A61K48/0033 , A61K48/005 , C07C227/16 , C07C227/18 , C07C229/16 , C07C233/36 , C07C235/10 , C07C255/24 , C07C271/20 , C07C275/14 , C07C279/12 , C07C279/24 , C07C279/28 , C07C279/32 , C07C311/05 , C07C335/08 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07D207/27 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D277/38 , C07F9/091 , C07K14/505
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
37.发明授权公开(公告)号：US12252704B2
公开(公告)日：2025-03-18
申请号：US17154309
申请日：2021-01-21
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Stephen Hoge , Kerry Benenato , Vladimir Presnyak , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Ding An , Staci Sabnis
Abstract: The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).
-
公开(公告)号：US12103955B2
公开(公告)日：2024-10-01
申请号：US16944014
申请日：2020-07-30
Applicant: MODERNATX, INC.
Inventor： Barry Ticho , Nadege Briancon-Eris , Zhinan Xia , Athanasios Dousis , Seymour de Picciotto , Vladimir Presnyak , Stephen Hoge , Iain Mcfadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: C12N15/62 , A61K31/7105 , A61K38/17 , A61K47/14 , A61K47/69 , A61K48/00 , A61P9/00 , C07K14/64 , C07K16/26 , C12N15/52 , A61K9/00 , A61K9/127 , A61K38/00
CPC classification number: C07K14/64 , A61K31/7105 , A61K38/1796 , A61K47/6929 , A61P9/00 , C07K16/26 , C12N15/52 , C12N15/62 , A61K9/0019 , A61K9/127 , A61K38/00 , C07K2319/00 , C07K2319/31
Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
-
公开(公告)号：US11504337B2
公开(公告)日：2022-11-22
申请号：US16515256
申请日：2019-07-18
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Vladimir Presnyak , Kerry Benenato , Stephen Hoge , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe
IPC: C12N15/11 , A61K9/51 , C12N9/90 , A61K9/127 , A61P3/00 , A61P43/00 , A61K38/52 , A61K48/00 , C12N15/52 , A61K38/00
Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
-
公开(公告)号：US11185510B2
公开(公告)日：2021-11-30
申请号：US16543102
申请日：2019-08-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai , Vladimir Presnyak , Stephen G. Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K38/20 , A61K9/51 , A61K48/00 , A61K38/17 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.068 seconds)
